Gauruv Bose1, Harold L Atkins2, Marjorie Bowman3, Mark S Freedman2. 1. Department of Neurology, The Ottawa Hospital Civic Campus, Ottawa, ON, Canada/Department of Medicine, University of Ottawa and The Ottawa Hospital Research Institute, Ottawa, ON, Canada. 2. Department of Medicine, University of Ottawa and The Ottawa Hospital Research Institute, Ottawa, ON, Canada. 3. Ambulatory Care, The Ottawa Hospital, Ottawa, ON, Canada.
Abstract
BACKGROUND: Fatigue is a common problem in multiple sclerosis (MS) affecting as many as 90% of patients. The Fatigue Impact Scale (FIS) is a validated measure of fatigue in MS patients. The cause of fatigue in MS is likely multifactorial, with some evidence that ongoing central nervous system (CNS) inflammation is a contributing factor. Immunoablation and autologous hematopoietic stem cell transplantation (aHSCT) have been shown to halt ongoing CNS inflammation. OBJECTIVE: To investigate whether halting all ongoing inflammation with aHSCT impacts FIS scores in patients with severe MS. METHODS: In the Canadian aHSCT study ( ClinicalTrials.gov , NCT01099930), 23 patients underwent aHSCT and had FIS prospectively collected every 6 months for 36 months of follow-up. Change in FIS was analysed by repeated-measures analysis of variance (RMANOVA) with multiple linear regression to determine independent predictors. RESULTS: The median FIS score decreased 36%, from 36 to 23 (p = 0.001), and four patients had 100% reduction. Improvement in FIS correlated with lower age and Expanded Disability Status Scale at baseline, as well as increased independence as evidenced by a return to gainful employment and even driving. CONCLUSION: Patients had significantly less fatigue on average after aHSCT. This may serve to better understand the contribution of ongoing CNS inflammation to fatigue peculiar to MS.
BACKGROUND:Fatigue is a common problem in multiple sclerosis (MS) affecting as many as 90% of patients. The Fatigue Impact Scale (FIS) is a validated measure of fatigue in MS patients. The cause of fatigue in MS is likely multifactorial, with some evidence that ongoing central nervous system (CNS) inflammation is a contributing factor. Immunoablation and autologous hematopoietic stem cell transplantation (aHSCT) have been shown to halt ongoing CNS inflammation. OBJECTIVE: To investigate whether halting all ongoing inflammation with aHSCT impacts FIS scores in patients with severe MS. METHODS: In the Canadian aHSCT study ( ClinicalTrials.gov , NCT01099930), 23 patients underwent aHSCT and had FIS prospectively collected every 6 months for 36 months of follow-up. Change in FIS was analysed by repeated-measures analysis of variance (RMANOVA) with multiple linear regression to determine independent predictors. RESULTS: The median FIS score decreased 36%, from 36 to 23 (p = 0.001), and four patients had 100% reduction. Improvement in FIS correlated with lower age and Expanded Disability Status Scale at baseline, as well as increased independence as evidenced by a return to gainful employment and even driving. CONCLUSION:Patients had significantly less fatigue on average after aHSCT. This may serve to better understand the contribution of ongoing CNS inflammation to fatigue peculiar to MS.
Entities:
Keywords:
Multiple sclerosis; fatigue; haematology; hematopoietic stem cell transplantation; neurology; quality of life
Authors: Simon Thebault; Daniel R Tessier; Hyunwoo Lee; Marjorie Bowman; Amit Bar-Or; Douglas L Arnold; Harold L Atkins; Vincent Tabard-Cossa; Mark S Freedman Journal: Neurol Neuroimmunol Neuroinflamm Date: 2019-08-08
Authors: Azza Ismail; Basil Sharrack; Riccardo Saccardi; John J Moore; John A Snowden Journal: Curr Opin Support Palliat Care Date: 2019-12 Impact factor: 2.302
Authors: Fiona Roberts; Helen Hobbs; Helen Jessop; Cristina Bozzolini; Joachim Burman; Raffaella Greco; Azza Ismail; Majid Kazmi; Kirill Kirgizov; Gianluigi Mancardi; Susan Mawson; Paolo A Muraro; Mathieu Puyade; Riccardo Saccardi; Barbara Withers; Bregje Verhoeven; Basil Sharrack; John A Snowden Journal: Front Neurol Date: 2020-12-11 Impact factor: 4.003
Authors: Simon Thebault; Hyunwoo Lee; Gauruv Bose; Daniel Tessier; Mohammad Abdoli; Marjorie Bowman; Jason Berard; Lisa Walker; Carolina A Rush; Heather MacLean; Ronald A Booth; Sridar Narayanan; Douglas L Arnold; Vincent Tabard-Cossa; Harold L Atkins; Amit Bar-Or; Mark S Freedman Journal: Ann Clin Transl Neurol Date: 2020-04-18 Impact factor: 4.511